{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:25:27Z","timestamp":1791433527060,"version":"4.3.3"},"reference-count":181,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Amphotericin B (AmB) has long stood as a cornerstone in the treatment of invasive fungal infections (IFIs), especially among immunocompromised patients. However, the landscape of antifungal therapy is evolving. New antifungal agents, boasting novel mechanisms of action and better safety profiles, are entering the scene, presenting alternatives to AmB\u2019s traditional dominance. This shift, prompted by an increase in the incidence of IFIs, the growing demographic of immunocompromised individuals, and changing patterns of fungal resistance, underscores the continuous need for effective treatments. Despite these challenges, AmB\u2019s broad efficacy and low resistance rates maintain its essential status in antifungal therapy. Innovations in AmB formulations, such as lipid complexes and liposomal delivery systems, have significantly mitigated its notorious nephrotoxicity and infusion-related reactions, thereby enhancing its clinical utility. Moreover, AmB\u2019s efficacy in treating severe and rare fungal infections and its pivotal role as prophylaxis in high-risk settings highlight its value and ongoing relevance. This review examines AmB\u2019s standing amidst the ever-changing antifungal landscape, focusing on its enduring significance in current clinical practice and exploring its potential future therapeutic adaptations.<\/jats:p>","DOI":"10.3390\/jof10040278","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:07:46Z","timestamp":1712729266000},"page":"278","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Amphotericin B in the Era of New Antifungals: Where Will It Stand?"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9494","authenticated-orcid":false,"given":"Karolina","family":"Akinosoglou","sequence":"first","affiliation":[{"name":"School of Medicine, University of Patras, 26504 Patras, Greece"},{"name":"Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil Angelos","family":"Rigopoulos","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Papageorgiou","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-1865","authenticated-orcid":false,"given":"Georgios","family":"Schinas","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Polyzou","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effrosyni","family":"Dimopoulou","sequence":"additional","affiliation":[{"name":"Hellenic Institute for the Study of Sepsis, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Gogos","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"3rd Department of Critical Care, Evgenidio Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kidd, S.E., Chen, S.C., Meyer, W., and Halliday, C.L. (2019). A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02903"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0609.2009.01391.x","article-title":"Diagnostic challenges and recent advances in the early management of invasive fungal infections","volume":"84","author":"Chandrasekar","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/TCRM.S3994","article-title":"Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?","volume":"4","author":"Zaragoza","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/jac\/dkq440","article-title":"Treatment and timing in invasive mould disease","volume":"66","author":"Maertens","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/molecules19011085","article-title":"Invasive fungal infections in the ICU: How to approach, how to treat","volume":"19","author":"Paramythiotou","year":"2014","journal-title":"Molecules"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zheng, Y.J., Xie, T., Wu, L., Liu, X.Y., Zhu, L., Chen, Y., Mao, E.Q., Han, L.Z., Chen, E.Z., and Yang, Z.T. (2021). Epidemiology, species distribution, and outcome of nosocomial Candida spp. bloodstream infection in Shanghai: An 11-year retrospective analysis in a tertiary care hospital. Ann. Clin. Microbiol. Antimicrob., 20.","DOI":"10.1186\/s12941-021-00441-y"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yang, Z.T., Wu, L., Liu, X.Y., Zhou, M., Li, J., Wu, J.Y., Cai, Y., Mao, E.Q., Chen, E.Z., and Lortholary, O. (2014). Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-241"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/myc.13082","article-title":"Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"63","author":"Ruhnke","year":"2020","journal-title":"Mycoses"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/jac\/dkac351","article-title":"Liposomal amphotericin B\u2014The past","volume":"77","author":"Jensen","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/jac\/dkac352","article-title":"Liposomal amphotericin B-the present","volume":"77","author":"Maertens","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/microbiolspec.FUNK-0002-2016","article-title":"Antifungal Drugs: The Current Armamentarium and Development of New Agents","volume":"4","author":"Robbins","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2008.01979.x","article-title":"Amphotericin B lipid preparations: What are the differences?","volume":"14","author":"Proffitt","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Faustino, C., and Pinheiro, L. (2020). Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010029"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.04723-14","article-title":"Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus","volume":"59","author":"Petraitis","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B","volume":"68","author":"Lewis","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, P., Chen, G., and Zhang, J. (2022). A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules, 27.","DOI":"10.3390\/molecules27041372"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.diagmicrobio.2013.04.001","article-title":"Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex","volume":"76","author":"Wade","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: A randomized, double-blind clinical trial of efficacy and safety","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2141.1998.00934.x","article-title":"A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology","volume":"103","author":"Clark","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/myc.12283","article-title":"Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: A real-life study","volume":"58","author":"Falci","year":"2015","journal-title":"Mycoses"},{"key":"ref_30","first-page":"206","article-title":"Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment","volume":"25","author":"Soriano","year":"2012","journal-title":"Rev. Esp. Quim."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1517\/17425255.2015.1042363","article-title":"A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity","volume":"11","author":"Karimzadeh","year":"2015","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00228-014-1642-9","article-title":"N-acetyl cysteine in prevention of amphotericin- induced electrolytes imbalances: A randomized, double-blinded, placebo-controlled, clinical trial","volume":"70","author":"Karimzadeh","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4103\/1735-5362.301343","article-title":"Comparison of intravenous sodium bicarbonate and sodium chloride combination versus intravenous sodium chloride hydration alone in reducing amphotericin B nephrotoxicity: A randomized clinical trial","volume":"15","author":"Karimzadeh","year":"2020","journal-title":"Res. Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.1991.214","article-title":"Effect of salt supplementation on amphotericin B nephrotoxicity","volume":"40","author":"Llanos","year":"1991","journal-title":"Kidney Int."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ota, Y., Obata, Y., Takazono, T., Tashiro, M., Wakamura, T., Takahashi, A., Shiozawa, Y., Miyazaki, T., Nishino, T., and Izumikawa, K. (2021). Association between potassium supplementation and the occurrence of acute kidney injury in patients with hypokalemia administered liposomal amphotericin B: A nationwide observational study. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02450-7"},{"key":"ref_36","first-page":"CD010481","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: Effects on kidney function","volume":"2015","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"ref_38","first-page":"149","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis","year":"2017","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Gangneux","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.00870-07","article-title":"Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products","volume":"52","author":"Olson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/mmy\/myu070","article-title":"Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice","volume":"53","author":"Olson","year":"2015","journal-title":"Med. Mycol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/myc.12585","article-title":"Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis","volume":"60","author":"Steimbach","year":"2017","journal-title":"Mycoses"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/ciy515","article-title":"Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial","volume":"68","author":"Jarvis","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1469-0691.2008.01982.x","article-title":"New dosing strategies for liposomal amphotericin B in high-risk patients","volume":"14 Suppl 4","author":"Ellis","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/jac\/dkh003","article-title":"Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis","volume":"52","author":"Martin","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1469-0691.2005.01262.x","article-title":"Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis","volume":"11","author":"Gavalda","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: An initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1473-3099(21)00203-6","article-title":"Global guideline for the diagnosis and management of rare yeast infections: An initiative of the ECMM in cooperation with ISHAM and ASM","volume":"21","author":"Chen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: Diagnosis and management of invasive aspergillosis in neonates and children","volume":"25","author":"Warris","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/IDR.S237815","article-title":"Emerging Invasive Fungal Infections: Clinical Features and Controversies in Diagnosis and Treatment Processes","volume":"13","author":"Zhang","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/cid\/cit006","article-title":"Finding the \u201cmissing 50%\u201d of invasive candidiasis: How nonculture diagnostics will improve understanding of disease spectrum and transform patient care","volume":"56","author":"Clancy","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","first-page":"106923","article-title":"Fungal infections: Their diagnosis and treatment in transplant recipients","volume":"2012","author":"George","year":"2012","journal-title":"Int. J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(15)70006-X","article-title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases","volume":"15","author":"Schelenz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.00945-09","article-title":"Effect of antifungal therapy timing on mortality in cancer patients with candidemia","volume":"54","author":"Taur","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1128\/AAC.05902-11","article-title":"Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients","volume":"56","author":"Spiess","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1164\/rccm.201906-1185ST","article-title":"Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline","volume":"200","author":"Hage","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_66","first-page":"117","article-title":"Empirical antifungal treatment: A valid alternative for invasive fungal infection","volume":"24","author":"Vallejo","year":"2011","journal-title":"Rev. Esp. Quim."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1439-0507.2009.01820.x","article-title":"Clinically relevant drug interactions of current antifungal agents","volume":"53","author":"Gubbins","year":"2010","journal-title":"Mycoses"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/myc.12330","article-title":"Antifungal drug resistance among Candida species: Mechanisms and clinical impact","volume":"58","author":"Sanguinetti","year":"2015","journal-title":"Mycoses"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijpharm.2017.04.013","article-title":"Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting","volume":"525","author":"Ballesteros","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2011.11.001","article-title":"Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment","volume":"125","author":"Pfaller","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance: An emerging clinical problem?","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","article-title":"The global problem of antifungal resistance: Prevalence, mechanisms, and management","volume":"17","author":"Perlin","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11908-018-0608-y","article-title":"The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases","volume":"20","author":"Schwartz","year":"2018","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Burks, C., Darby, A., Gomez Londono, L., Momany, M., and Brewer, M.T. (2021). Azole-resistant Aspergillus fumigatus in the environment: Identifying key reservoirs and hotspots of antifungal resistance. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009711"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.01128-10","article-title":"Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2,441 patients","volume":"55","author":"Lortholary","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/ciy473","article-title":"Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/myc.12213","article-title":"Our 2014 approach to breakthrough invasive fungal infections","volume":"57","author":"Maschmeyer","year":"2014","journal-title":"Mycoses"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bmt.2015.181","article-title":"Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis","volume":"50","author":"Montesinos","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1093\/jac\/dkw199","article-title":"A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis","volume":"71","author":"Biehl","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3324\/haematol.2011.042598","article-title":"The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: The HEMA e-Chart Project","volume":"96","author":"Pagano","year":"2011","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hammond, E.E., McDonald, C.S., Vestbo, J., and Denning, D.W. (2020). The global impact of Aspergillus infection on COPD. BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-01259-8"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jinf.2016.04.022","article-title":"Aspergillus infections in cystic fibrosis","volume":"72","author":"King","year":"2016","journal-title":"J. Infect."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.09-1103","article-title":"The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis","volume":"137","author":"Amin","year":"2010","journal-title":"Chest"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/mmy\/myw121","article-title":"Aspergillus-related pulmonary diseases in lung transplantation","volume":"55","author":"Pasupneti","year":"2017","journal-title":"Med. Mycol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1164\/rccm.202004-1038LE","article-title":"COVID-19-associated Pulmonary Aspergillosis","volume":"202","author":"Rijpstra","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000489474","article-title":"Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives","volume":"96","author":"Cadranel","year":"2018","journal-title":"Respiration"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S1473-3099(17)30309-2","article-title":"Pulmonary and sinus fungal diseases in non-immunocompromised patients","volume":"17","author":"Denning","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1093\/mmy\/myy070","article-title":"Chronic pulmonary aspergillosis update: A year in review","volume":"57","author":"Barac","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_95","first-page":"e4538","article-title":"Treating Allergic Bronchopulmonary Aspergillosis: A Review","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/CMR.00140-18","article-title":"Aspergillus fumigatus and Aspergillosis in 2019","volume":"33","author":"Latge","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/myc.12869","article-title":"Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project","volume":"62","author":"Bassetti","year":"2019","journal-title":"Mycoses"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"56","DOI":"10.15585\/mmwr.mm7002e3","article-title":"Candida auris Outbreak in a COVID-19 Specialty Care Unit\u2014Florida, July\u2013August 2020","volume":"70","author":"Prestel","year":"2021","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3201\/eid2611.203504","article-title":"Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April\u2013July 2020","volume":"26","author":"Chowdhary","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Posteraro, B., Torelli, R., Vella, A., Leone, P.M., De Angelis, G., De Carolis, E., Ventura, G., Sanguinetti, M., and Fantoni, M. (2020). Pan-Echinocandin-Resistant Candida glabrata Bloodstream Infection Complicating COVID-19: A Fatal Case Report. J. Fungi, 6.","DOI":"10.20944\/preprints202008.0198.v1"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00134-017-4731-2","article-title":"Intensive care medicine research agenda on invasive fungal infection in critically ill patients","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"Meersseman","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1469-0691.2009.03015.x","article-title":"Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome","volume":"16","author":"Guinea","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients with COVID-19: A Prospective Study","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s10096-020-03923-7","article-title":"Influenza-associated aspergillosis in critically-ill patients-a retrospective bicentric cohort study","volume":"39","author":"Waldeck","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13613-021-00818-4","article-title":"Poor outcome associated with mucormycosis in critically ill hematological patients: Results of a multicenter study","volume":"11","author":"Jestin","year":"2021","journal-title":"Ann. Intensive Care"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e200430","DOI":"10.1590\/0074-02760200430","article-title":"Invasive fungal disease in humans: Are we aware of the real impact?","volume":"115","author":"Firacative","year":"2020","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-023-01891-8","article-title":"Rezafungin: First Approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Carvalhaes, C., Messer, S.A., Rhomberg, P.R., and Castanheira, M. (2020). Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00099-20"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"James, K.D., Laudeman, C.P., Malkar, N.B., Krishnan, R., and Polowy, K. (2017). Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01541-16"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_113","unstructured":"(2024, April 01). Clinical Trials.gov. NCT04368559: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04368559."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(23)00551-0","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: Pooled data from two prospective randomised controlled trials","volume":"24","author":"Thompson","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1016\/j.bmcl.2010.06.005","article-title":"Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives","volume":"20","author":"Nakamoto","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Arendrup, M.C., Chowdhary, A., Astvad, K.M.T., and J\u00f8rgensen, K.M. (2018). APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01225-18"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Hager, C.L., Larkin, E.L., Long, L., Zohra Abidi, F., Shaw, K.J., and Ghannoum, M.A. (2018). In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A\/APX001 against Candida auris. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02319-17"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Huband, M.D., Flamm, R.K., Bien, P.A., and Castanheira, M. (2019). In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1706 Fungal Isolates Collected during an International Surveillance Program in 2017. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00840-19"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"McCarty, T.P., and Pappas, P.G. (2021). Antifungal Pipeline. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.732223"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen, K.M., Astvad, K.M.T., Hare, R.K., and Arendrup, M.C. (2018). EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00487-18"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkz078","article-title":"In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies","volume":"74","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/jac\/dkaa562","article-title":"In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species","volume":"76","author":"Singh","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zhang, J., Liu, H., Xi, L., Chang, Y.C., Kwon-Chung, K.J., and Seyedmousavi, S. (2021). Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.00256-21"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1093\/jac\/dkaa351","article-title":"In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies","volume":"75","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"106105","DOI":"10.1016\/j.ijantimicag.2020.106105","article-title":"In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus","volume":"56","author":"Kirchhoff","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jix479","article-title":"Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus","volume":"217","author":"Negri","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_134","unstructured":"Maertens, J.A., Verweij, P.E., Lanuza, E.F., Harvey, E.L., Dane, A., Zinzi, D., Rex, J.H., and Chen, S.C. (2022). Open Forum Infectious Diseases, Oxford University Press."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Apgar, J.M., Wilkening, R.R., Parker, D.L., Meng, D., Wildonger, K.J., Sperbeck, D., Greenlee, M.L., Balkovec, J.M., Flattery, A.M., and Abruzzo, G.K. (2021). Ibrexafungerp: An orally active \u03b2-1,3-glucan synthesis inhibitor. Bioorganic Med. Chem. Lett., 32.","DOI":"10.1016\/j.bmcl.2020.127661"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Messer, S.A., Rhomberg, P.R., Borroto-Esoda, K., and Castanheira, M. (2017). Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00161-17"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Jallow, S., and Govender, N.P. (2021). Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor. J. Fungi, 7.","DOI":"10.3390\/jof7030163"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Nunnally, N.S., Etienne, K.A., Angulo, D., Lockhart, S.R., and Berkow, E.L. (2019). In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01692-19"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-021-00376-x","article-title":"Pharmacokinetics and Pharmacodynamics of Ibrexafungerp","volume":"22","author":"McCarthy","year":"2022","journal-title":"Drugs R&D"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ofid\/ofac492.064","article-title":"871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)","volume":"Volume 9","author":"Thompson","year":"2022","journal-title":"Open Forum Infectious Diseases"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: A Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ajog.2019.10.088","article-title":"A phase 2b, dose-selection study evaluating the efficacy and safety of oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis (DOVE)","volume":"221","author":"Angulo","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med. Chem. Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"624.e1","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","article-title":"A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis","volume":"73","author":"Brand","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bjd.19224","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail","volume":"184","author":"Elewski","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jps.10173","article-title":"Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system","volume":"91","author":"Segarra","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.44.6.1463-1469.2000","article-title":"Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model","volume":"44","author":"Zarif","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Skipper, C.P., Atukunda, M., Stadelman, A., Engen, N.W., Bangdiwala, A.S., Hullsiek, K.H., Abassi, M., Rhein, J., Nicol, M.R., and Laker, E. (2020). Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00838-20"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"ii21","DOI":"10.1093\/jac\/dkac353","article-title":"Liposomal amphotericin B-the future","volume":"77","author":"Hoenigl","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Rajendran, R., Sherry, L., Deshpande, A., Johnson, E.M., Hanson, M.F., Williams, C., Munro, C.A., Jones, B.L., and Ramage, G. (2016). A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.00915"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3109\/10428194.2010.496504","article-title":"Approaches to the early treatment of invasive fungal infection","volume":"51","author":"Ito","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1111\/j.1439-0507.2010.01947.x","article-title":"Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC\/MSG 2008 definitions of invasive mould disease","volume":"54","author":"Cornely","year":"2011","journal-title":"Mycoses"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jiac.2021.06.013","article-title":"Efficacy of early administration of liposomal amphotericin B in patients with septic shock: A nationwide observational study","volume":"27","author":"Tashiro","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Whaley, S.G., Berkow, E.L., Rybak, J.M., Nishimoto, A.T., Barker, K.S., and Rogers, P.D. (2016). Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.02173"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled Liposomal Antimicrobial Delivery in Lung Infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/myc.12294","article-title":"Nebulised liposomal amphotericin B for Aspergillus lung diseases: Case series and literature review","volume":"58","author":"Godet","year":"2015","journal-title":"Mycoses"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13054-021-03728-w","article-title":"Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis\/aspergillus tracheobronchitis","volume":"25","author":"Rutsaert","year":"2021","journal-title":"Crit. Care"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl. Int."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2102218","DOI":"10.1183\/13993003.02218-2021","article-title":"Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: A randomised, multicentre trial","volume":"59","author":"Godet","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3062.2007.00209.x","article-title":"Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: A retrospective study","volume":"9","author":"Lowry","year":"2007","journal-title":"Transpl. Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","article-title":"Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Pharmacokinetics and safety","volume":"28","author":"Monforte","year":"2009","journal-title":"J. Heart Lung Transplant."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pupt.2008.09.001","article-title":"Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial","volume":"21","author":"Slobbe","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MCC.0000000000000230","article-title":"Fungal infections in the ICU: Advances in treatment and diagnosis","volume":"21","author":"Tumbarello","year":"2015","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkx032","article-title":"Invasive mould infections in the ICU setting: Complexities and solutions","volume":"72","author":"Bassetti","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_171","first-page":"175","article-title":"Epidemiology and treatment approaches in management of invasive fungal infections","volume":"3","author":"Kriengkauykiat","year":"2011","journal-title":"Clin. Epidemiol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10157-020-01989-3","article-title":"The clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: A nationwide observational study","volume":"25","author":"Obata","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Azoulay, E., Timsit, J.F., Lautrette, A., Legriel, S., Max, A., Ruckly, S., Misset, B., Cohen, Y., and Wolff, M. (2017). Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177093"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1186\/cc8117","article-title":"Treatment of candidemia and invasive candidiasis in the intensive care unit: Post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B","volume":"13","author":"Dupont","year":"2009","journal-title":"Crit. Care"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics4010001","article-title":"The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia","volume":"4","author":"Bouza","year":"2014","journal-title":"Antibiotics"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.micinf.2016.01.002","article-title":"Candida albicans biofilms: Development, regulation, and molecular mechanisms","volume":"18","author":"Gulati","year":"2016","journal-title":"Microbes Infect."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","article-title":"Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study","volume":"39","author":"Kett","year":"2011","journal-title":"Crit. Care Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1128\/AAC.02344-12","article-title":"Liposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilms","volume":"57","author":"Ramage","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Barantsevich, N., and Barantsevich, E. (2022). Diagnosis and Treatment of Invasive Candidiasis. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060718"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7883\/yoken.JJID.2016.574","article-title":"Time-Lapse Tracking of Candida tropicalis Biofilm Formation and the Antifungal Efficacy of Liposomal Amphotericin B","volume":"70","author":"Kawai","year":"2017","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ijmm.2014.08.012","article-title":"Production of biofilm by Candida and non-Candida spp. isolates causing fungemia: Comparison of biomass production and metabolic activity and development of cut-off points","volume":"304","author":"Escribano","year":"2014","journal-title":"Int. J. Med. Microbiol."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/4\/278\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:25:34Z","timestamp":1760106334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/4\/278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":181,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jof10040278"],"URL":"https:\/\/doi.org\/10.3390\/jof10040278","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]}}}